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Saphenous vein graft has been the most com-
monly used as a bypass conduit for patients who
undergo coronary and other peripheral arterial
revascularization because it has various advantages,
such as availability and graft length, over the inter-
nal mammary artery graft.1-6 Nevertheless, vein
graft occlusion remains a major short-term and
long-term problem. By 5 years after the bypass graft
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Purpose: To clarify the mechanisms of structural changes underlying vein graft stenosis
that limits efficacy of bypass grafting operation, we examined the accumulation and dis-
tribution of various extracellular matrix (ECM) components during neointima forma-
tion in rabbit vein grafts and analyzed their correlation with proliferation and pheno-
typic modulation of smooth muscle cells (SMCs).
Methods and Results: An autologous external jugular vein graft was transplanted into the
carotid artery in 25 rabbits. After the restoration of blood flow, the graft was markedly
dilated. Medial SMCs in the graft appeared to be injured, and they began to proliferate at
day 4 and subsequently migrated and formed the neointima at day 7. The neointima
observed at days 7 and 14 contained ECM components, including type I collagen, heparan
sulfate, and chondroitin sulfate, and the intimal SMCs were phenotypically modulated
from the differentiated-type (SM2-positive and SM embryonic–negative) to the dediffer-
entiated-type (SM2-negative and SM embryonic–positive) as determined with immuno-
stainings for myosin heavy chain isoforms. The intimal SMC proliferation was maximal at
2 weeks and then decreased rapidly. However, the neointima continued to thicken there-
after throughout the 6-month period of the experiment, and ECM accumulation, such as
type I collagen and decorin, a small dermatan sulfate proteoglycan, was a prominent fea-
ture observed in the hypocellular region of the deep intima from 2 months after the trans-
plantation. The phenotype of the intimal SMCs gradually returned to the differentiated-
type from the deep intima after 2 months, but a small number of the intimal SMCs
remained in the dedifferentiated phenotype even at 6 months after the operation.
Conclusion: The neointima in the vein graft was formed initially by means of migration
and proliferation of the phenotypically modulated, dedifferentiated-type SMCs and con-
tinued to thicken by means of sustained ECM accumulation, including type I collagen
and decorin, in association with the prolonged presence of the dedifferentiated-type
SMCs. These chronologic features in cell kinetics and ECM accumulation may con-
tribute to the frequent occurrence of graft wall thickening that occurs in the vein grafts.
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operation, 20% to 50% of the grafts may occlude,
and thus, 5% to 10% percent of patients undergo
repeat bypass grafting surgery.1-4 The sequences of
the histopathologic changes that occur in the
venous arterial grafts in humans can be divided into
three stages: acute thrombotic changes (within 1
month), fibrointimal hyperplasia (within 1 year),
and atherosclerotic changes (after the first postop-
erative year). The stenosis and occlusion of the graft
principally result from fibrointimal hyperplasia 
and its secondary changes, such as superimposed
atheroma and its rupture.3-6
Intimal hyperplasia is the universal response of a
vein graft to insertion into the arterial circulation and
is considered to result from migration and prolifera-
tion of intimal SMCs originating from the media.7,8
This phenomenon may represent an adaptation of a
vein graft imposed by arterial hemodynamic environ-
ment, but, on the other hand, it underlies luminal
stenosis and its secondary changes, which may lead to
vein graft failure. Therefore, it is important to know
the mechanisms of this structural change that occurs
in the venous arterial grafts for establishment of the
prophylactic and therapeutic strategies to prevent
graft stenosis and occlusion.
Several recent reports described the time course of
medial and intimal thickening in autologous venous
arterial grafts in experimental animals, with attention
to proliferation of smooth muscle cells (SMCs) 
and deposition of extracellular matrix (ECM).7-13
Involvement of ECM in the regulation of proliferation
and the phenotypic modulation of SMCs has been a
focus of the research on the pathogenesis of neointima
formation after arterial injury.14-16 Among the various
ECM components, decorin, a dermatan sulfate pro-
teoglycan, was recently shown to be accumulated in
the advanced atherosclerotic lesions in humans, and its
potential roles have been indicated particularly in reg-
ulation of SMC proliferation and the phenotypic mod-
ulation during atherogenesis.17,18 Elastin is also
recently shown to have not only a structural role but
also a regulatory function during arterial developmen-
tal remodeling through regulation of SMC prolifera-
tion.19,20 Nevertheless, the temporal and spatial asso-
ciations of these cell kinetics and the accumulation and
distribution of various ECM components have not
been examined in vein graft models.
In the present study, therefore, we applied the
immunohistochemical techniques to determine the
distribution of various ECM components during
neointima formation in autologous rabbit carotid
artery vein grafts and to compare the temporal and
spatial association of different ECM components
with the measures of SMC proliferation and pheno-
typic modulation during this process.
MATERIALS AND METHODS
Animals
Adult male New Zealand white rabbits, weighing
2.5 to 2.9 kg (Kbl-NZW, Nagano, Japan) and fed on
a standard diet (ORC4, Oriental Yeast Corp, Osaka,
Japan), were used. This investigation conformed with
the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, Com-
mission on Life Sciences, National Research Council.
Washington: National Academy Press, 1996).
Surgical procedures
General anesthesia was induced with xylazine
hydrochloride (5 mg/kg intramuscular) and
atropine (0.02 mg/kg intramuscular) and main-
tained with inhalation of 1.2% sevoflurane. A mid-
line incision was made in the ventral area of the
neck after infiltration with 1% lidocaine, the sec-
ond tributary of the external jugular vein was dis-
sected free of surrounding tissue by a “no touch”
technique,21 and all side branches were secured
with an 8-0 polypropylene monofilament ligature
(Nescosuture, Nippon Shoji Co, Tokyo, Japan).
After intravenous injection of heparin (300 U/kg
body weight), the vein, approximately 30 mm in
length, was harvested and irrigated gently with
heparinized iso-osmotic sodium chloride solution
(9 g/L) containing papaverine hydrochloride (0.6
mg/L). The vein was stored in the same solution
at room temperature for 5 to 10 minutes until
needed. After both ends of the exposed right com-
mon carotid artery were clamped, the middle 10-
mm length of the artery was cut out and the har-
vested vein was interposed into the carotid artery
to maintain the original venous flow orientation
by means of end-to-end anastomosis with the cuff
technique.22 This technique necessitated no sutur-
ing of anastomosed vessels and thus helped to
minimize surgical injury of the vessel wall. The
cut-off ends of the artery both were passed
through 2 mm–long cuffs made from a catheter
introducer sheath (4F; Medikit Co, Tokyo, Japan),
everted over, and then inserted into the vein to be
implanted. Anastomosis was completed with cir-
cumferential ligation with 7-0 ligature, and the
neck wound then was closed in layers. In the sham
operation, the same procedure including intra-
venous heparin injection was performed except for
transection and anastomosis of the vein to examine
the effect of dissection on the venous structure.
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Patency examination and tissue preparation
Ultrasonic duplex scanning was used to examine
the patency of the vein graft twice a week after the
operation. Five vein grafts were harvested for each
time point at 4, 7, and 14 days and at 2 and 6 months
after grafting for histologic investigation. An addi-
tional five veins were obtained without transplanta-
tion as controls, and the sham-treated veins were har-
vested at 4, 7 and 14 days after the operation.
Each harvested vein graft was divided into two
parts. One half was immersion fixed in methanol
Carnoy’s fixative (60% methanol, 30% chloroform,
10% acetic acid) for 24 hours, dehydrated through
three changes of methanol, and embedded in
paraffin. The other half was frozen in OCT com-
pound (Miles Scientific, Tokyo, Japan) in a cry-
omold in liquid nitrogen. General histopathologic
investigations were performed on paraffin sections
with hematoxylin and eosin, elastica van Gieson’s
solution (EVG), and Masson trichrome (MT)
staining.
Antibodies used for immunohistochemistry
Mouse monoclonal antibodies against smooth
muscle–specific a -actin (1A4, DAKO, Glostrup,
Denmark), rabbit macrophages (RAM11, DAKO),
and proliferating cell nuclear antigen (PCNA; PC-
10, DAKO) were used as specific markers for SMCs,
macrophages, and proliferating cells, respectively, on
paraffin-embedded sections.23,24 To identify various
components of ECM, we used mouse monoclonal
antibodies specific to type I collagen (clone I-8H5,
Fuji Chemical Co, Toyama, Japan),25 chondroitin
sulfate (CS) glycosaminoglycan (clone CS56, Sigma
Chemical Co, St Louis, Mo),26 heparan sulfate (HS)
glycosaminoglycan (clone HepSS-1, Seikagaku Co,
Tokyo, Japan),27 and core protein of dermatan sul-
fate proteoglycan (decorin; 6B6, Seikagaku Co).28
On frozen sections, myosin heavy chain (MHC) iso-
forms (SM2 and SM embryonic [SMemb]) were
immunostained to identify SMC phenotypes.
SMemb is a nonmuscle MHC isoform and is
expressed in SMCs at embryonic and neonatal stages
and when they are phenotypically modulated toward
the dedifferentiated-type but down regulated in the
adults.29-32 SM2 is shown to be expressed in a
reversed manner. Therefore, SMemb is a useful
marker for the dedifferentiated-type SMCs, and
SM2 is a marker for the differentiated-type.33,34 The
monoclonal antibodies against MHC isoforms were
generated and kindly provided by Prof Ryozo Nagai
(Gunma University, Japan).29-33 The specificities of
the primary antibodies we used in the present study




The immunoperoxidase streptavidin-biotin com-
plex system (DAKO) with nickel chloride (NiCl)
color modification was used as described previous-
ly.34 Briefly, 3-m m sections were deparaffinized and
rehydrated before endogenous peroxidase activity
was blocked with 3% hydrogen peroxide and then
preincubated with 3% normal rabbit serum in tris-
HCl-buffered saline solution (TBS, pH 7.6) for 20
minutes. The primary antibodies diluted at optimal
concentration were applied to the sections and incu-
bated for 30 minutes. They then were serially incu-
bated with biotinylated rabbit anti-mouse (or anti-
goat) immunoglobulin G (IgG; 1:400; DAKO) for
30 minutes, streptavidin-biotinylated horseradish
peroxidase complex (1:100; DAKO) for 30 minutes,
and 0.05% 3,3´-diaminobenzidine (Sigma Chemical
Co) dissolved in 200 mL TBS containing 0.2 mL of
30% hydrogen peroxide and 1.0 mL of 8% NiCl solu-
tion for 10 minutes, with washing in TBS between
each procedure. The sections then were counter-
stained with methylgreen, dehydrated through a
graded alcohol series, permeated with xylene, and
covered with coverslips. To confirm specificities of
these immunostainings, the primary antibodies were
replaced with mouse IgG purified from the pool of
nonimmune serum (Organon Teknika Co, Osaka,
Japan). These treatments served as negative controls
and showed no positive stainings.
Immunohistochemistry on frozen sections
Frozen sections, 3 m m thick, were cut from fresh
frozen blocks of tissue and immunostained for SM2
and SMemb with the immunoperoxidase strepta-
vidin-biotin complex system with NiCl color modi-
fication. Because fixation affects the sensitivity of
immunostaining, none was used. The primary anti-
bodies were diluted 1:1000, and biotinylated rabbit
anti-mouse (Fab)2 (DAKO) was applied as the sec-
ond antibody at 1:400 dilution. As negative con-
trols, nonimmune mouse IgG was applied to the
adjacent serial sections instead of the primary anti-
bodies and showed no positive stainings.
Quantification of intimal areas, cell numbers, cell
density, and smooth muscle cell proliferation
Two paraffin sections sampled from each graft were
used for quantitative analysis after the exclusion of
those containing anastomosis microscopically. Intimal
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areas were measured after EVG staining with a com-
puterized image analysis system (SP500, Olympus,
Tokyo, Japan). The numbers of PCNA-positive nuclei
and of all nuclei were counted in the intima on sections
immunostained for PCNA with methylgreen nuclear
counterstaining, and the frequency of cell proliferation
was expressed as the PCNA index, defined as the ratio
of the number of PCNA-positive nuclei to all nuclei in
the intima. The cell density in the intima was calculated
as the division of the number of all nuclei by intimal
areas in the same specimen. The areas of mural throm-
bi, if any, were excluded from the measurements.
Statistical analysis of the time-dependent changes of
the intimal areas, the PCNA index, and the cell densi-
ties in the intima were examined by means of one-way
analysis of variance and post hoc Fisher exact test.
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Fig 1. Color photomicrographs show structures of tribu-
tary of external jugular vein before transplantation (con-
trol vein). Adjacent sections of paraffin-embedded tissue
were stained with Masson trichrome (A) or elastica van
Gieson’s solution (B) or immunohistochemically for a -
actin (C), and those from frozen tissue were stained for
SM2 (D), SMemb (E), and nonimmunized IgG (F). Bar
in panel F, 20 m m (applies to all panels).
Fig 2. Temporal changes of intimal thickening expressed
as intimal area (A) and cell proliferation expressed as pro-
liferating nuclear cell antigen (PCNA) index and cell den-
sity in the intima (B) after transplantation. Each point is
mean ± SD of measurements of 10 sections in vein grafts
dissected at corresponding time points. Statistically signif-
icant differences are shown as *P < .05, compared with the
values at previous time points as determined with analysis
of variance and post hoc Fisher exact test. @ indicates no
significant difference.
RESULTS
Histology of control veins
The vein harvested from the second tributary of
the external jugular vein for transplantation has a
thin wall structure consisting of a single layer of
endothelial cells lying on the internal elastic lamina
and a few layers of a -actin–positive medial SMCs
interspersed with elastic fibers (Fig 1A-C). Accord-
ing to MHC isoform immunostainings, these medi-
al SMCs in the control veins tested positive for SM2
and negative for SMemb (Fig 1D,E), indicating the
differentiated phenotype. No cells were stained pos-
itively for PCNA or RAM11. According to the
ECM immunostainings, the media showed patchy
deposition of type I collagen, CS, and HS, but no
decorin deposition (data not shown). On the other
hand, the adventitia was stained diffusely with col-
lagen I and decorin and faintly with CS and HS.
The sham-treated veins showed neither intimal
thickenings nor significant alteration in the
immunostainings for a -actin, PCNA, and MHC
isoforms at days 4, 7 and 14.
Graft patency after transplantation
Among the 29 animals examined, four were
excluded from the study because of graft occlusion
as detected by means of ultrasonic duplex scanning.
Graft occlusion was detected within the first 4 days,
and the lumens were occluded with mixed thrombi
containing platelets and large numbers of erythro-
cytes as determined by means of histopathologic
examination.
Time course of neointimal thickening and SMC
proliferation
The vein graft transplanted into the carotid
artery showed wall thickening with neointima for-
mation. As shown in Fig 2A, the neointima began to
form at day 7 and continued to thicken gradually up
to 6 months after the operation. The intimas in the
control veins and the grafts at day 4 consisted only
of covering endothelial cells, and thus, their areas
were negligible.
Fig 2B shows temporal changes of PCNA index,
which represents the frequency of PCNA-positive
proliferating cells, in the neointima. This was maxi-
mal on day 14 and decreased thereafter, but SMC
proliferation continued to be detectable and did not
return to the baseline levels even at 6 months after
the transplantation. Fig 2 also illustrates the tempo-
ral changes in the cell density in the intima formed
in the grafts and the indicated decrease of the cell
density at 2 months and later.
The histologic changes that caused these alter-
ations in the intimal thickness, cell proliferation, and
cell density in the neointima were examined in vein
grafts and described in the following sections.
Histologic changes in vein grafts
Four days after transplantation. After transplan-
tation into the carotid artery, the vein graft was
markedly dilated in response to the exposure of arteri-
al circulation. At day 4 after the operation, some of the
covering endothelial cells were sloughed away and the
media and the adventitia were edematous and infiltrat-
ed with fibrinous exudate (Fig 3A,B). Medial SMCs
showed loss of a -actin immunostaining (Fig 4A), and
there were many spindle-shaped cells in the adventitia
immunostained with a -actin and oriented in irregular
directions. PCNA immunostaining showed that the
remaining endothelial cells, medial SMCs, and adven-
titial spindle-shaped cells were proliferating focally at
day 4 (Fig 4B), but the neointima had not formed yet
in any of the grafts. MHC immunostaining revealed
loss of SM2 immunostaining in the media and focal
expression of SMemb in the media and the adventitia
(Fig 5A,B). The internal elastic lamina was principally
preserved, but elastic fibers in the media were some-
times discontinuous. Many inflammatory cells, includ-
ing macrophages and neutrophils, infiltrated the
adventitia. No apparent changes were observed in
ECM components as compared with the control veins.
Luminal thrombosis was not observed in the experi-
mental group, although the occluded grafts were
excluded from the study.
Seven to 14 days after transplantation. At day
7, the inflammatory cell infiltration subsided in the
graft walls, but it remained in the adventitia to some
extent. The neointima consisting of a -actin–positive
SMCs was formed in all grafts, although it was not
circumferential (Fig 3C,D). The intimal SMCs were
stained positively for SMemb and negatively for
SM2 on MHC immunostaining, indicating pheno-
typic modulation to the dedifferentiated-type (Fig
5C,D), and many of these SMCs were proliferating
as determined by means of PCNA immunostaining
(Fig 4C,D). The collagen and elastic fibers were
invisible in the neointima with MT and EVG stain-
ing (Fig 3C,D), but ECM immunostaining showed
deposition of type I collagen, HS (Fig 6A,B), and
CS (data not shown). Decorin immunostaining was
positive only in the adventitia and not in the neoin-
tima or the media (Fig 6C). The a -actin–positive
spindle-shaped cells were also present into the
adventitia, and the external elastic lamina was par-
tially discontinuous.
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At day 14, the neointima became circumferen-
tial, and its thickness continued to increase from day
7 to 14 (Fig 2A). Many intimal SMCs appeared to
be proliferating as determined by means of PCNA
immunostaining (Fig 4E,F) and retained the dedif-
ferentiated phenotype (Fig 5E,F). EVG staining
showed formation of elastic fibers in the neointima
within thin and discontinuous lamellae (Fig 3F).
Collagen fibers became visible in MT staining (Fig
3E), and ECM immunostaining showed accumula-
tion of type I collagen, HS (Fig 6D,E), and CS (data
not shown) in the neointima but no decorin (Fig
6F). Macrophages immunostained with RAM11
were rarely observed in the neointima or in the
media, and the adventitia contained small numbers
of inflammatory cells, including macrophages (data
not shown). The a -actin–positive spindle cells were
scattered not only in the media but also in the
adventitia (Fig 4E). According to the MHC isoform
immunostaining, the medial cells were differentiat-
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Fig 3. Color photomicrographs showing vein grafts transplanted into carotid arteries at days
4 (A,B), 7 (C,D) and 14 (E,F) and at 2 months (G,H) and 6 months (I,J) after surgery.
Adjacent sections from each paraffin-embedded tissue were stained with Masson trichrome
(A,C,E,G,I), and elastica van Gieson’s solution (B,D,F,H,J). Arrowheads indicate internal
elastic lamina. Bar in panel J, 20 m m (applies to all panels).
ed-type SMCs, but the nature of adventitial cells,
being positive for SMemb and negative for SM2,
may be dedifferentiated-type of SMCs, but it
remains unclear (Fig 5E,F).
Two to 6 months after transplantation. The
neointima continued to increase in thickness during
the period from day 14 to 6 months (Fig 2A). A small
but significant number of PCNA-positive SMCs
remained present in the neointima (Fig 4G,H) and
may have contributed to the progression of intimal
thickening. However, the calculated cell density in the
neointima decreased with time, particularly at 2
months and later (Fig 2B). By means of histologic
observation, the extracellular spaces between intimal
SMCs in the neointima appeared to expand at 2 and
6 months as compared with that at day 14, and the
elastic and collagen fibers in the neointima thickened
and became more continuous at this stage (Fig 3G-J).
In ECM immunostaining, decorin deposition was
seen to have begun in hypocellular regions localized
deep within the neointima (Fig 6I,L) along with
deposition of type I collagen (Fig 6G,J). Interestingly,
the areas with decorin deposition were devoid of HS,
and HS, on the other hand, accumulated in the super-
ficial and cellular regions of the neointima (Fig
6H,K). Type I collagen and CS accumulated in both
regions but more extensively in deep and hypocellular
regions of the neointima. Mural fibrin thrombi were
focally found on the luminal surface of the advanced
neointima in association with macrophage infiltration
in all grafts obtained at 6 months, and such changes
were also observed in two of five grafts at 2 months.
Many of the intimal SMCs remained positive for
SMemb at 2 months, and these dedifferentiated-
type SMCs tended to localize in the superficial
region of the intima (Fig 5H). On the other hand,
some of the intimal SMCs in deep regions were
reverted to the differentiated phenotype, indicated
by SM2-positive SMCs (Fig 5G). As described pre-
viously, the deep regions in the neointima showed
unique display of ECM at this time point, and there-
fore, it is intriguing to find a possible association of
the phenotypic modulation of vascular SMCs with
ECM accumulation. At 6 months, most of the inti-
mal SMCs returned to the SM2-positive differenti-
ated phenotype from the deep intima (Fig 5I), but
the dedifferentiated-type SMCs were still scattter-
ingly found in the intima (Fig 5J).
DISCUSSION
Most autologous vein grafts transplanted into
the arterial circulation undergo graft wall thickening
as a result of smooth muscle growth and deposition
of extracellular matrix.3-6 This phenomenon can be
interpreted as an adaptation to the exposed arterial
circulation, such as high arterial pressure, shear
stress, and oxygen concentration, and the term
“arterialization” has been used. With careful obser-
vations of the histologic appearance, however, the
vein grafts never become arteries even if they remain
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Fig 3 Cont’d. Adjacent sections from each paraffin-embedded tissue were stained with
Masson trichrome (A,C,E,G,I), and elastica van Gieson’s solution (B,D,F,H,J). Arrowheads
indicate internal elastic lamina. Bar in panel J, 20 m m (applies to all panels).
patent for a long period. Indeed, vein graft thicken-
ing is characterized histologically by fibrointimal
hyperplasia, which progresses rapidly and is suscepti-
ble to secondary atherosclerotic changes as com-
pared with that formed in the arteries. Therefore,
pathogenesis of this fibrointimal hyperplasia in vein
graft needs to be clarified to establish prophylactic
regimens for the prevention of graft occlusion.
The surgical procedures, including dissection and
harvesting of the veins, preservation of the veins
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Fig 4. Color photomicrographs showing vein grafts transplanted into carotid arteries at days 4
(A,B), 7 (C,D) and 14 (E,F), and at 2 months (G,H) and 6 months (I,J,K) after surgery.
Adjacent sections from each paraffin-embedded tissue were stained immunohistochemically for a -
actin (A,C,E,G,I), proliferating cell nuclear antigen (B,D,F,H,J), and nonimmunized IgG (K).
Dashed line in I indicates the internal elastic lamina. Bar in panel K, 20 m m (applies to all panels).
before transplantation, vessel anastomosis, and sec-
ondary ischemia resulting from the interruption of
vasa vasorum, may result in such injury.7,8 The sham-
operated veins showed no pathologic findings until
day 14, but this cannot exclude a possibility of the
vessel injury with harvesting and preservation of the
vein or anastomosis. We previously performed suture
technique for vein graft anastomosis, and the grafts
showed a fibrocellular neointima formation similar to
those observed in the present study. However, the
intimal thickness varied to a greater extent among the
animals, probably because of the extent of the injury
during the operation. Therefore, we used the cuff
technique for anastomosis, which necessitated no
suture, to minimize surgical injury of the vessel wall
and variation of operation time and intimal thicken-
ings among the experiments. In our present study, we
focused on the structural changes underlying graft
wall thickening as related to the “adaptation” process
to arterial circulation and not to anastomosis. We
excluded the specimens containing anastomosis from
the quantitative analysis because the area of anasto-
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Fig 4 Cont’d. Color photomicrographs showing vein grafts transplanted into carotid arteries at
6 months (I,J,K) after surgery. Adjacent sections from each paraffin-embedded tissue were stained
immunohistochemically for a -actin (A,C,E,G,I), proliferating cell nuclear antigen (B,D,F,H,J),
and nonimmunized IgG (K). Dashed line in I indicates the internal elastic lamina. Bar in panel K,
20 m m (applies to all panels).
mosis showed various histologic appearance, such as
foreign body reaction in the adventitia even in our
suture-less model. The damage caused by anastomo-
sis may be an important factor leading to graft steno-
sis and occlusion, but we are unable to comment on
the effect of anastomosis on the vein graft stenosis
from the present study.
The cell kinetics leading to neointima formation
after vascular injury have been investigated exten-
sively in the balloon injury model of rat carotid
arteries.35 Recently, we reported the spatial and tem-
poral distributions of SMC proliferation and pheno-
typic modulation during neointima formation in
stent-induced regional injury in rabbit aortas.34 In
this model, SMC proliferation was transient and
ceased by 2 weeks after stent implantation and the
intimal thickening increased little after 2 weeks,
which is consistent with the previous observations in
balloon-injury models.35 Furthermore, the pheno-
type of intimal SMCs returned from the dedifferen-
tiated-type to the differentiated-type by the second
month after stenting. In the venous arterial grafts,
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Fig 5. Photomicrographs showing immunohistochemical staining for myosin heavy chain iso-
forms, SM2 (A,C,E,G,I) and SMemb (B,D,F,H,I), in frozen sections of vein grafts dissected
at days 4 (A,B), 7 (C,D), and 14 (E,F) and at 2 months (G,H) and 6 months (I,J) after trans-
plantation. Bar in panel J, 20 m m (applies to all panels). 
the cell kinetics underlying fibrointimal hyperplasia
have been described in some experimental animal
models, including rabbits, pigs, and nonhuman pri-
mates.9-13 These studies showed that the graft wall
thickened mainly as a result of transient SMC prolif-
eration, which occurred within 4 weeks, and that the
ECM accumulation persisted longer in the vein
graft. The results of the present study are in agree-
ment with these previous reports and further clari-
fied that SMC proliferation leading to neointima
formation in vein grafts occurs in association with
the phenotypic modulation of SMCs to the dediffer-
entiated-type and that SMC proliferation and the
dedifferentiated-type SMCs remained in the neointi-
ma even at 6 months after surgery. These prolonged
cell kinetics compared with those in balloon-induced
or stent-induced injury in the arteries contribute to
advanced fibrointimal hyperplasia in the vein grafts.
The migration and proliferation of SMCs are
induced in the neointima, possibly through the release
of growth factors, including basic fibroblast growth
factor, platelet-derived growth factor (PDGF), and
transforming growth factor-b (TGF-b ), from the graft
wall.7,8,36,37 Implantation of a vein graft into the arte-
rial circulation may cause graft dilatation and mechan-
ical stretching and induce damage of endothelial cells
and medial SMCs and insudation of plasma and leuko-
cytes into the walls.38 Such shear stress may also influ-
ence the release of PDGF and basic fibroblast growth
factor by arterial SMCs,39 and PDGF-B gene contains
cis-acting shear stress response element in the 5´ pro-
motor region.40 Therefore, mechanical forces stretch-
ing the venous graft wall may activate production and
release of these growth factors and may be responsible
for the accelerated and prolonged cell kinetics in
venous arterial grafts. Indeed, a rigid external cast to
prevent overstretching of the vein grafts was reported
to be somewhat effective in reducing neointima for-
mation in vein graft models,41 and this effect is pro-
posed to be mediated by the control of expression and
the secretion of PDGF.42
Accumulation of ECM proteins appeared to be
another important factor accelerating fibrointimal
hyperplasia in vein grafts. Production of excessive
connective tissue in relation to the phenotypic mod-
ulation of contractile-type SMCs into the synthetic-
type has been postulated to represent a response to
vascular injury.14,15,43 Because synthetic SMCs cor-
respond to the dedifferentiated-type SMCs,33 the
prolonged presence of dedifferentiated-type SMCs
shown in the present study correlated well with the
sustained ECM deposition in the neointima from 2
weeks to 6 months after transplantation. Among the
various ECM components, decorin, a dermatan sul-
fate proteoglycan, showed an interesting distribu-
tion: decorin accumulated in the hypocellular
regions of the deep intima along with type I collagen
from 2 months after surgery and contributed to inti-
mal thickening. It is to be noted that the dedifferen-
tiated SMCs tend to be localized in the superficial
layer at 2 and 6 months and that the differentiated
SMCs tend to be localized in the deep intima. This
localization is consistent with the distribution of
heparan sulfate proteoglycan and decorin, respec-
tively. Such an association may suggest a diversity in
the regulatory role of ECM components in SMC
kinetics in vivo. In humans, decorin accumulation
was recently shown in the hypocellular regions of
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Fig 5 Cont’d. Photomicrographs showing immunohistochemical staining for myosin heavy
chain isoforms, SM2 (A,C,E,G,I) and SMemb (B,D,F,H,I), in frozen sections of vein grafts
dissected at days 4 (A,B), 7 (C,D), and 14 (E,F) and at 2 months (G,H) and 6 months (I,J)
after transplantation. Bar in panel J, 20 m m (applies to all panels). 
advanced atheromatous lesions and cardiac allograft
diseases, preferentially in the vicinity of macrophage
accumulation.17,18 Therefore, decorin deposition
during the neointima formation in a venous arterial
graft is an interesting feature that suggests a similar-
ity to atherosclerosis and may be related to the
superimposition of atherosclerotic changes.
Decorin is known to bind to collagen and TGF-
b and is considered to play a role in the inhibition of
fibrillogenesis and collagen synthesis through the
neutralization of TGF-b activity.16,44 Our observa-
tion that decorin accumulates in the hypocellular
region in the neointima of vein graft supports this
hypothesis. Moreover, decorin was recently reported
to suppress cell growth associated with upregulation
of p21 (WAF1), an inhibitor of cyclin-dependent
kinases,45 and thus, it is possible to function as a
growth inhibitor. There have been many reports
examining the roles in the cell kinetics and pheno-
typic modulation of various ECM components,
including collagen, heparan sulfate proteoglycans,
and CS proteoglycans in vitro.46-48 Therefore, the
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Fig 6. Photomicrographs showing immunohistochemical staining for extracellular matrix
components, type I collagen (A,D,G,J), heparan sulfate proteoglycan (B,E,H,K), and decorin
(C,F,I,L) in paraffin sections of vein grafts dissected at days 7 (A-C) and 14 (D-F) and at 2
months (G-I) and 6 months (J-L) after transplantation. Areas marked with * indicate hypocel-
lular region localized deep in the intima. Bar in panel K, 20 m m (applies to all panels).
diversity of distribution of these proteoglycans and
other ECM proteins shown in the present study sug-
gests differences in the potential roles of these ECM
proteins and their glycosaminoglycan chains during
neointima formation in vein grafts.
The present study showed that fibrointimal
hyperplasia in vein grafts was formed initially by
migration and proliferation of the SMCs, which orig-
inated from the media and were phenotypically mod-
ulated to the dedifferentiated-type SMCs after dam-
age of the graft wall and continued to thicken as a
result of sustained ECM accumulation, including
type I collagen and decorin in association with the
prolonged presence of the dedifferentiated-type
SMCs. These prolonged cell kinetics and ECM accu-
mulation are considered to contribute to the acceler-
ated graft wall thickening that occurs in the vein
grafts. To prevent such intimal hyperplasia in vein
grafts, therefore, phenotypic modulation of SMCs
and synthesis and deposition of ECM should be
properly regulated with appropriate timing. Recently,
the application of gene (or antisense oligonu-
cleotides) therapy has been suggested to be effective
for prevention of vein graft stenosis,49 and we are
now pursuing the possibility of transfection of genes
capable of regulating the cell cycle and phenotypic
modulation of SMCs in this vein graft model.50
We thank Dr Ryozo Nagai, Gunma University, for the
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